Javascript must be enabled to continue!
Discordant Evidence on Corticosteroids in Sepsis: A Meta-Research Study
View through CrossRef
Abstract
Background
Despite numerous randomized controlled trials (RCTs) and systematic reviews (SRs), current sepsis guidelines continue to issue only weak recommendations for corticosteroids. We examined the clinical scope, underlying study pools, and mortality conclusions of SRs evaluating corticosteroids for sepsis.
Methods
We conducted a meta-research study of SRs on corticosteroids in sepsis (2015– 2025), extracting SR characteristics, mortality results, and included RCTs. Study-pool overlap was assessed using an SR×RCT inclusion matrix, Jaccard similarity (J), and hierarchical clustering. SRs and RCTs were classified according to standardized Population, Intervention, Comparison, Outcome (PICO) profiles. We explored discordance in short-term mortality conclusions among clinically comparable SRs and potential associations with study-pool composition, target populations, and methodological characteristics.
Results
Forty-two SRs including 121 unique RCTs were identified. More than half of pairwise SR comparisons shared no RCTs, and only three pairs showed high overlap (J>0.8). SRs addressing similar intervention and target population profiles frequently relied on different study pools. Among 38 SRs with short-term mortality meta-analyses, 15 (39%) reported benefit and 23 (61%) no evidence of effect. Discordance occurred exclusively among SRs evaluating broad, non-specific corticosteroid strategies; conclusions were consistent for hydrocortisone plus fludrocortisone (benefit) and hydrocortisone, ascorbic acid, and thiamine (no evidence of effect). SRs including sepsis ± shock populations more frequently reported benefit than those restricted to septic shock (62% vs 22%), although estimates were imprecise. No single methodological or clinical factor consistently explained discordance.
Conclusions
SRs addressing apparently similar clinical questions frequently synthesized different underlying evidence bases and reported discordant conclusions. Guideline developers should therefore consider not only methodological quality and reported PICO, but also whether the RCTs included in an SR adequately represent the intended clinical question. Clinically coherent evidence syntheses may improve the interpretability of pooled treatment effects and support more targeted corticosteroid therapy in sepsis.
Key messages
SRs addressing clinically similar questions frequently relied on different and only partially overlapping sets of RCTs.
Discordant mortality conclusions occurred exclusively among SRs evaluating non-specific broad corticosteroid strategies, whereas SRs of hydrocortisone plus fludrocortisone and hydrocortisone, ascorbic acid, and thiamine reported consistent findings.
Differences in target populations (sepsis ± shock vs septic shock) may contribute to discordant findings, although no single methodological or clinical factor consistently explained the observed discordance.
Clinical guideline developers should evaluate the clinical scope and underlying evidence base of SRs, not only their methodological quality, when formulating recommendations.
Title: Discordant Evidence on Corticosteroids in Sepsis: A Meta-Research Study
Description:
Abstract
Background
Despite numerous randomized controlled trials (RCTs) and systematic reviews (SRs), current sepsis guidelines continue to issue only weak recommendations for corticosteroids.
We examined the clinical scope, underlying study pools, and mortality conclusions of SRs evaluating corticosteroids for sepsis.
Methods
We conducted a meta-research study of SRs on corticosteroids in sepsis (2015– 2025), extracting SR characteristics, mortality results, and included RCTs.
Study-pool overlap was assessed using an SR×RCT inclusion matrix, Jaccard similarity (J), and hierarchical clustering.
SRs and RCTs were classified according to standardized Population, Intervention, Comparison, Outcome (PICO) profiles.
We explored discordance in short-term mortality conclusions among clinically comparable SRs and potential associations with study-pool composition, target populations, and methodological characteristics.
Results
Forty-two SRs including 121 unique RCTs were identified.
More than half of pairwise SR comparisons shared no RCTs, and only three pairs showed high overlap (J>0.
8).
SRs addressing similar intervention and target population profiles frequently relied on different study pools.
Among 38 SRs with short-term mortality meta-analyses, 15 (39%) reported benefit and 23 (61%) no evidence of effect.
Discordance occurred exclusively among SRs evaluating broad, non-specific corticosteroid strategies; conclusions were consistent for hydrocortisone plus fludrocortisone (benefit) and hydrocortisone, ascorbic acid, and thiamine (no evidence of effect).
SRs including sepsis ± shock populations more frequently reported benefit than those restricted to septic shock (62% vs 22%), although estimates were imprecise.
No single methodological or clinical factor consistently explained discordance.
Conclusions
SRs addressing apparently similar clinical questions frequently synthesized different underlying evidence bases and reported discordant conclusions.
Guideline developers should therefore consider not only methodological quality and reported PICO, but also whether the RCTs included in an SR adequately represent the intended clinical question.
Clinically coherent evidence syntheses may improve the interpretability of pooled treatment effects and support more targeted corticosteroid therapy in sepsis.
Key messages
SRs addressing clinically similar questions frequently relied on different and only partially overlapping sets of RCTs.
Discordant mortality conclusions occurred exclusively among SRs evaluating non-specific broad corticosteroid strategies, whereas SRs of hydrocortisone plus fludrocortisone and hydrocortisone, ascorbic acid, and thiamine reported consistent findings.
Differences in target populations (sepsis ± shock vs septic shock) may contribute to discordant findings, although no single methodological or clinical factor consistently explained the observed discordance.
Clinical guideline developers should evaluate the clinical scope and underlying evidence base of SRs, not only their methodological quality, when formulating recommendations.
Related Results
Prevalence of Sepsis in Hematopoietic Stem Cell Transplant Recipients: Organism-Specific Analysis
Prevalence of Sepsis in Hematopoietic Stem Cell Transplant Recipients: Organism-Specific Analysis
Introduction:
Patients who undergo hematopoietic stem cell transplants are at a high risk of infection. With the emergence of multidrug-resistant organisms (MDR),...
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
Neurological Complications in Sepsis
Neurological Complications in Sepsis
Background: Sepsis is a medical emergency that requires immediate assessment and management. Sepsis can affect patients at any age group which increases the number of sepsis cases....
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
“CORRELATION OF PROCALCITONIN WITH SEPSIS SCREEN AND BLOOD CULTURE IN NEONATAL SEPSIS”
“CORRELATION OF PROCALCITONIN WITH SEPSIS SCREEN AND BLOOD CULTURE IN NEONATAL SEPSIS”
BACKGROUND – Sepsis in neonates may be difcult to differentiate from other conditions, because the clinical signs are non-specic. It is a
common cause of morbidity and mortality ...
Impacts of the COVID-19 pandemic on sepsis incidence, etiology and hospitalization costs in France: a retrospective observational study
Impacts of the COVID-19 pandemic on sepsis incidence, etiology and hospitalization costs in France: a retrospective observational study
Abstract
Background
Sepsis is a serious medical condition that causes long-term morbidity and high mortality, annually affectin...
Sepsis-Related Mortality Rates and Trends Based on Site of Infection
Sepsis-Related Mortality Rates and Trends Based on Site of Infection
OBJECTIVES:
Sepsis is defined as life-threatening organ dysfunction triggered by an underlying infection. A recent study noted that the overall sepsis-related mortality...
To Determine The Association Of Serum Neopterin Levels In Sepsis
To Determine The Association Of Serum Neopterin Levels In Sepsis
Abstract
ABSTRACT
Background: Sepsis is a leading cause of death worldwide. Sepsis results in state of multiorgan dysfunction in the body. Early identification and appropri...

